Sat, Jul 12, 2014, 5:16 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Jan 15, 2013 12:14 PM Flag

    Why should I buy OMER now?

    Wow - I've never seen such enthusiasm over ignorant comments. Phase III "failures" - of the three phase III trials the company has completed, the two lens replacement trials have had over-the-top positive results and the knee surgery trial had mixed results. Please provide us with the competing drugs that are cheaper and more effective than the company's "witches brew" - you don't even know the pricing that the lens replacement drug will be, but you know that there are cheaper drugs? If having a shelf registration in place was the reason to sell/avoid a company's stock, then not many small-cap biotechs, who are always needing to raise money, would be worth buying. The debt raise is a good thing - obviously the lender is looking at the lens replacement trial/pending NDA & launch as reason to advance additional funds - again, most small cap biotechs would love to be able to borrow money at 9.25%, instead of pushing further dilution on their shareholders, but for you it is a negative - just proves your ignorance!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ..."wow" -- per Omeros' press releases:

      "Each of the APIs in OMS103HP are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles."

      ...those three drugs in the joint solution are Afrin, Orudis, and Elavil...in the eye solution they are Orudis and phenylephrine...all of them have REAL CHEAP generic alternatives that are more easily administered than an irrigating solution...

      ...OMER would try to argue, per the patent:

      "It is impossible to obtain an equivalent therapeutic effect by delivering similarly dosed agents via systemic (e.g., intravenous, subcutaneous, intramuscular or oral) routes of drug administration since drugs given systemically are subject to first- and second-pass metabolism."

      ...that is pure unadulterated baloney -- I would have preferred a stronger word but prissy Yahoo would censor me if I did...

      ...OMER offers absolutely no evidence to support any claim that "irrigating" with their solution produces a higher and/or more effective local concentration than can be achieved by IV or oral dosing...

      ...in FACT, oral or IV administration probably would be MORE effective since once an irrigation stops, then those drugs' effects should dissipate quickly while the oral/IV will persist...

      ...as regards the mydriatics, there are a half dozen or so generic eyedrops available that work every bit as well as any irrigating solution -- what do you think they use currently in ophthalmological surgery?...

      ...in order to prove superiority, OMER would have to do trials comparing using its solutions to using orally or IV administered drugs and drugs currently in use...but they haven't been doing that now, have they?...

      ...why not?...because they already know that their "witches' brew" would fail...

      ...the only two things OMER's solutions have are "jack" and -- oops -- Yahoo's censor says you have to guess the other one...HAW, HAW, HAW!!!!...

      Sentiment: Strong Sell

      • 1 Reply to rrtzrealmd
      • You first talk of oral/IV drugs that are available to provide mydriasis and then speak to generic drops - which is it? Anybody that has had an eye exam knows there are drops that are used to dialate the pupil - similar drops are used prior to surgery and the OMS302 irrigation drug is used to maintain the dialation during surgery - that is the comparison in the trial - how dialation changes with and without the use of OMS302 during surgery. Obviously, once the surgery has begun it is apparently not kosher to use additional drops, or that would be done and OMS302 would have no purpose. I find it fascinating that people believe a company would waste millions of dollars on developing a drug and pushing it through the clinic where there is no apparent need? I'm not saying OMS302 is a blockbuster indication, but the idea that there is no market for this drug because the need is already being met with drugs currently in use seems awfully simplistic - again, why would Wedbush put the market potential at $600M if there generic alternatives already being utilized as effectively. Also, any time doctors can generate a medical result without having to use a systemic drug, they will opt for it - avoiding potential side effects and problems with oral/IV drugs has tremendous value, especially when dealing with senior patients, who typically are on numerous prescriptions, already, presenting systemic interaction risks. When it comes to the knee surgery drug, the benefit is reducing the use of systemic anti-inflammatories and pain killers post-surgery, which is something doctors are clearly in favor of, so to say that there is no utility in OMS103HP is, again, simplistic.

    • My favorite ignorant tidbit is in another post where shareholders are somehow responsible to pay back company debt.

      • 1 Reply to scubamoe
      • ...well, let's see...my favorite "ignorant tidbit" is someone who doesn't understand -- apparently -- that the company belongs to the shareholders...

        ...the cash and whatever other assets exist belong to THEM...ditto for the debt and whatever other liabilities exist...

        ...so, yes, that 20 MILLION dollars plus the 9.25% interest it's accumulating is going to come out of THEIR pockets...

        Sentiment: Strong Sell

 
OMER
14.63+0.02(+0.14%)Jul 11 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.